A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 42
Summary
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Primary Objective: 1. To assess 2 year probability of OS in high risk patients undergoing a myeloablative 2 step HSCT utilizing strategies to decrease relapse. Secondary Objective: To assess relapse incidence at 2 years post-HSCT of patients undergoing treatment on this protocol. To assess regimen r...
Primary Objective: 1. To assess 2 year probability of OS in high risk patients undergoing a myeloablative 2 step HSCT utilizing strategies to decrease relapse. Secondary Objective: To assess relapse incidence at 2 years post-HSCT of patients undergoing treatment on this protocol. To assess regimen related toxicity and GVHD incidence at 2 years post-HSCT and severity in patients undergoing treatment on this protocol. To assess the consistency and pace of engraftment. To assess the pace of T cell and B cell immune recovery.
Tracking Information
- NCT #
- NCT03032783
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Dolores Grosso, DNP Sidney Kimmel Cancer Center at Thomas Jefferson University
Get Well Soon